Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
How often do you monitor pulmonary function tests in patients with fibrotic lung disease?
Related Questions
Would you restart sirolimus for a decline in lung function or pneumothoraces in a pregnant patient with LAM?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Do you administer immunosuppression to patients with idiopathic NSIP who have normal lung function and mild to moderate respiratory symptoms?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
